IBDEI0Q9 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11797,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11797,1,3,0)
;;=3^Polyarteritis nodosa
;;^UTILITY(U,$J,358.3,11797,1,4,0)
;;=4^M30.0
;;^UTILITY(U,$J,358.3,11797,2)
;;=^5011738
;;^UTILITY(U,$J,358.3,11798,0)
;;=M31.0^^46^574^5
;;^UTILITY(U,$J,358.3,11798,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11798,1,3,0)
;;=3^Hypersensitivity angiitis
;;^UTILITY(U,$J,358.3,11798,1,4,0)
;;=4^M31.0
;;^UTILITY(U,$J,358.3,11798,2)
;;=^60279
;;^UTILITY(U,$J,358.3,11799,0)
;;=M31.31^^46^574^23
;;^UTILITY(U,$J,358.3,11799,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11799,1,3,0)
;;=3^Wegener's granulomatosis w/ renal involvement
;;^UTILITY(U,$J,358.3,11799,1,4,0)
;;=4^M31.31
;;^UTILITY(U,$J,358.3,11799,2)
;;=^5011745
;;^UTILITY(U,$J,358.3,11800,0)
;;=N28.89^^46^574^6
;;^UTILITY(U,$J,358.3,11800,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11800,1,3,0)
;;=3^Kidney & Ureter Disorders,Oth Specified
;;^UTILITY(U,$J,358.3,11800,1,4,0)
;;=4^N28.89
;;^UTILITY(U,$J,358.3,11800,2)
;;=^88007
;;^UTILITY(U,$J,358.3,11801,0)
;;=E85.4^^46^574^11
;;^UTILITY(U,$J,358.3,11801,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11801,1,3,0)
;;=3^Organ-limited amyloidosis
;;^UTILITY(U,$J,358.3,11801,1,4,0)
;;=4^E85.4
;;^UTILITY(U,$J,358.3,11801,2)
;;=^5003017
;;^UTILITY(U,$J,358.3,11802,0)
;;=M32.14^^46^574^2
;;^UTILITY(U,$J,358.3,11802,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11802,1,3,0)
;;=3^Glomerular disease in systemic lupus erythematosus
;;^UTILITY(U,$J,358.3,11802,1,4,0)
;;=4^M32.14
;;^UTILITY(U,$J,358.3,11802,2)
;;=^5011757
;;^UTILITY(U,$J,358.3,11803,0)
;;=M32.15^^46^574^16
;;^UTILITY(U,$J,358.3,11803,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11803,1,3,0)
;;=3^Tubulo-interstitial neuropathy in SLE
;;^UTILITY(U,$J,358.3,11803,1,4,0)
;;=4^M32.15
;;^UTILITY(U,$J,358.3,11803,2)
;;=^5011758
;;^UTILITY(U,$J,358.3,11804,0)
;;=M34.0^^46^574^13
;;^UTILITY(U,$J,358.3,11804,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11804,1,3,0)
;;=3^Progressive systemic sclerosis
;;^UTILITY(U,$J,358.3,11804,1,4,0)
;;=4^M34.0
;;^UTILITY(U,$J,358.3,11804,2)
;;=^5011778
;;^UTILITY(U,$J,358.3,11805,0)
;;=E85.81^^46^574^7
;;^UTILITY(U,$J,358.3,11805,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11805,1,3,0)
;;=3^Light Chain (AL) Amyloidosis
;;^UTILITY(U,$J,358.3,11805,1,4,0)
;;=4^E85.81
;;^UTILITY(U,$J,358.3,11805,2)
;;=^5151302
;;^UTILITY(U,$J,358.3,11806,0)
;;=E85.82^^46^574^24
;;^UTILITY(U,$J,358.3,11806,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11806,1,3,0)
;;=3^Wild-Type Transthyretin-Related (ATTR) Amyloidosis
;;^UTILITY(U,$J,358.3,11806,1,4,0)
;;=4^E85.82
;;^UTILITY(U,$J,358.3,11806,2)
;;=^5151303
;;^UTILITY(U,$J,358.3,11807,0)
;;=E85.89^^46^574^1
;;^UTILITY(U,$J,358.3,11807,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11807,1,3,0)
;;=3^Amyloidosis,Other
;;^UTILITY(U,$J,358.3,11807,1,4,0)
;;=4^E85.89
;;^UTILITY(U,$J,358.3,11807,2)
;;=^334034
;;^UTILITY(U,$J,358.3,11808,0)
;;=M31.10^^46^574^15
;;^UTILITY(U,$J,358.3,11808,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11808,1,3,0)
;;=3^Thrombotic Microangiopathy,Unspec
;;^UTILITY(U,$J,358.3,11808,1,4,0)
;;=4^M31.10
;;^UTILITY(U,$J,358.3,11808,2)
;;=^5161189
;;^UTILITY(U,$J,358.3,11809,0)
;;=Z87.442^^46^575^1
;;^UTILITY(U,$J,358.3,11809,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11809,1,3,0)
;;=3^Personal Hx of Urinary Calculi
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Q9 3803 printed Dec 13, 2024@01:53:39 Page 2
IBDEI0Q9 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11797,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,11797,1,3,0)
+4 ;;=3^Polyarteritis nodosa
+5 ;;^UTILITY(U,$J,358.3,11797,1,4,0)
+6 ;;=4^M30.0
+7 ;;^UTILITY(U,$J,358.3,11797,2)
+8 ;;=^5011738
+9 ;;^UTILITY(U,$J,358.3,11798,0)
+10 ;;=M31.0^^46^574^5
+11 ;;^UTILITY(U,$J,358.3,11798,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,11798,1,3,0)
+14 ;;=3^Hypersensitivity angiitis
+15 ;;^UTILITY(U,$J,358.3,11798,1,4,0)
+16 ;;=4^M31.0
+17 ;;^UTILITY(U,$J,358.3,11798,2)
+18 ;;=^60279
+19 ;;^UTILITY(U,$J,358.3,11799,0)
+20 ;;=M31.31^^46^574^23
+21 ;;^UTILITY(U,$J,358.3,11799,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,11799,1,3,0)
+24 ;;=3^Wegener's granulomatosis w/ renal involvement
+25 ;;^UTILITY(U,$J,358.3,11799,1,4,0)
+26 ;;=4^M31.31
+27 ;;^UTILITY(U,$J,358.3,11799,2)
+28 ;;=^5011745
+29 ;;^UTILITY(U,$J,358.3,11800,0)
+30 ;;=N28.89^^46^574^6
+31 ;;^UTILITY(U,$J,358.3,11800,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,11800,1,3,0)
+34 ;;=3^Kidney & Ureter Disorders,Oth Specified
+35 ;;^UTILITY(U,$J,358.3,11800,1,4,0)
+36 ;;=4^N28.89
+37 ;;^UTILITY(U,$J,358.3,11800,2)
+38 ;;=^88007
+39 ;;^UTILITY(U,$J,358.3,11801,0)
+40 ;;=E85.4^^46^574^11
+41 ;;^UTILITY(U,$J,358.3,11801,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,11801,1,3,0)
+44 ;;=3^Organ-limited amyloidosis
+45 ;;^UTILITY(U,$J,358.3,11801,1,4,0)
+46 ;;=4^E85.4
+47 ;;^UTILITY(U,$J,358.3,11801,2)
+48 ;;=^5003017
+49 ;;^UTILITY(U,$J,358.3,11802,0)
+50 ;;=M32.14^^46^574^2
+51 ;;^UTILITY(U,$J,358.3,11802,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,11802,1,3,0)
+54 ;;=3^Glomerular disease in systemic lupus erythematosus
+55 ;;^UTILITY(U,$J,358.3,11802,1,4,0)
+56 ;;=4^M32.14
+57 ;;^UTILITY(U,$J,358.3,11802,2)
+58 ;;=^5011757
+59 ;;^UTILITY(U,$J,358.3,11803,0)
+60 ;;=M32.15^^46^574^16
+61 ;;^UTILITY(U,$J,358.3,11803,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,11803,1,3,0)
+64 ;;=3^Tubulo-interstitial neuropathy in SLE
+65 ;;^UTILITY(U,$J,358.3,11803,1,4,0)
+66 ;;=4^M32.15
+67 ;;^UTILITY(U,$J,358.3,11803,2)
+68 ;;=^5011758
+69 ;;^UTILITY(U,$J,358.3,11804,0)
+70 ;;=M34.0^^46^574^13
+71 ;;^UTILITY(U,$J,358.3,11804,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,11804,1,3,0)
+74 ;;=3^Progressive systemic sclerosis
+75 ;;^UTILITY(U,$J,358.3,11804,1,4,0)
+76 ;;=4^M34.0
+77 ;;^UTILITY(U,$J,358.3,11804,2)
+78 ;;=^5011778
+79 ;;^UTILITY(U,$J,358.3,11805,0)
+80 ;;=E85.81^^46^574^7
+81 ;;^UTILITY(U,$J,358.3,11805,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,11805,1,3,0)
+84 ;;=3^Light Chain (AL) Amyloidosis
+85 ;;^UTILITY(U,$J,358.3,11805,1,4,0)
+86 ;;=4^E85.81
+87 ;;^UTILITY(U,$J,358.3,11805,2)
+88 ;;=^5151302
+89 ;;^UTILITY(U,$J,358.3,11806,0)
+90 ;;=E85.82^^46^574^24
+91 ;;^UTILITY(U,$J,358.3,11806,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,11806,1,3,0)
+94 ;;=3^Wild-Type Transthyretin-Related (ATTR) Amyloidosis
+95 ;;^UTILITY(U,$J,358.3,11806,1,4,0)
+96 ;;=4^E85.82
+97 ;;^UTILITY(U,$J,358.3,11806,2)
+98 ;;=^5151303
+99 ;;^UTILITY(U,$J,358.3,11807,0)
+100 ;;=E85.89^^46^574^1
+101 ;;^UTILITY(U,$J,358.3,11807,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,11807,1,3,0)
+104 ;;=3^Amyloidosis,Other
+105 ;;^UTILITY(U,$J,358.3,11807,1,4,0)
+106 ;;=4^E85.89
+107 ;;^UTILITY(U,$J,358.3,11807,2)
+108 ;;=^334034
+109 ;;^UTILITY(U,$J,358.3,11808,0)
+110 ;;=M31.10^^46^574^15
+111 ;;^UTILITY(U,$J,358.3,11808,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,11808,1,3,0)
+114 ;;=3^Thrombotic Microangiopathy,Unspec
+115 ;;^UTILITY(U,$J,358.3,11808,1,4,0)
+116 ;;=4^M31.10
+117 ;;^UTILITY(U,$J,358.3,11808,2)
+118 ;;=^5161189
+119 ;;^UTILITY(U,$J,358.3,11809,0)
+120 ;;=Z87.442^^46^575^1
+121 ;;^UTILITY(U,$J,358.3,11809,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,11809,1,3,0)
+124 ;;=3^Personal Hx of Urinary Calculi
